AVTX Earnings

Quarterly EPS
$0.98
Q3 2024
$-3.43
Q4 2024
$-1.25
Q1 2025
$-1.92
Q2 2025
$-2.19
Q3 2025
$-0.75
Q4 2025
$-0.98
Q1 2026
$-0.83
Q2 2026
Latest RevenueN/A
Latest Net Income-36358000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.830-36358000+56.8%
Q1 2026-$0.980-19630000+21.6%
Q4 2025-$0.7559.0K-13720000-69.3%+78.1%
Q3 2025-$2.190-30625000-100.0%-323.5%
Q2 2025-$1.920-20765000-145.6%
Q1 2025-$1.250-13149000+99.1%
Q4 2024-$3.43192.0K-35339000-66.4%
Q3 2024$0.98249.0K23.0M+5.5%+103.7%
Q2 2024$4.21098.5M
Q1 2024-$141.140-121290000
Q4 2023571.0K-8168000
Q3 2023-$26.83236.0K-5228000
Avalo Therapeutics (AVTX) — Earnings